M Rinaldi1, F Semeraro2, F Chiosi3, A Russo2, M R Romano4, M C Savastano5, R dell'Omo6, C Costagliola6,7. 1. Eye Clinic, Department of Ophthalmology, Seconda Università degli Studi di Napoli, Naples, Italy. 2. Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, Brescia, Italy. 3. Eye Clinic, Department of Medicine and Health Sciences, University of Molise, Via Francesco De Sanctis 1, 86100, Campobasso, Italy. flaviachiosi@yahoo.it. 4. Eye Clinic, Department of Neuroscience, University Federico II, Naples, Italy. 5. Department of Ophthalmology, Catholic University "Sacro Cuore, A. Gemelli", Rome, Italy. 6. Eye Clinic, Department of Medicine and Health Sciences, University of Molise, Via Francesco De Sanctis 1, 86100, Campobasso, Italy. 7. IRCCS Neuromed, Pozzilli, Isernia, Italy.
Abstract
BACKGROUND: To demonstrate the efficacy of intravitreal ranibizumab (IVR) in combination with reduced-fluence photodynamic therapy (RF-PDT) in patients with choroidal neovascularization (CNV) secondary to pathologic myopia. METHODS:Sixty patients affected by myopic CNV (mCNV) were randomized to receive either ranibizumab 0.5 mg monotherapy (RM; n = 20), standard fluence PDT (SF-PDT, n = 20) or RF-PDT combination therapy (n = 20). Subsequently, IVR was injected as needed. All patients were evaluated for 48 weeks. RESULTS:Mean BCVA change at 48 weeks was + 0.2 and +15 letters with SF or RFPDT plus ranibizumab, respectively, compared with +16.8 letters with RM. At 48 weeks, mean central foveal thickness (CFT) decrease from baseline was 58 ± 15 μm, 91.4 ± 43.8 μm, and 85 ± 41.5 μm for the verteporfin SF, RF and RM groups, respectively. Macular sensitivity improvement was + 0.4 db, + 1.9 dB and + 2.7 dB for the verteporfin SF, RF and RM groups, respectively. CONCLUSIONS:Ranibizumab monotherapy or combined with RF-PDT improved BCVA and macular sensitivity in patients affected by mCNV, whereas CFT results were reduced. SF-PDT combination regimen mostly stabilized vision at 48 weeks. Among all groups, the RF-PDT seemed to reduce the number of ranibizumab retreatments.
RCT Entities:
BACKGROUND: To demonstrate the efficacy of intravitreal ranibizumab (IVR) in combination with reduced-fluence photodynamic therapy (RF-PDT) in patients with choroidal neovascularization (CNV) secondary to pathologic myopia. METHODS: Sixty patients affected by myopic CNV (mCNV) were randomized to receive either ranibizumab 0.5 mg monotherapy (RM; n = 20), standard fluence PDT (SF-PDT, n = 20) or RF-PDT combination therapy (n = 20). Subsequently, IVR was injected as needed. All patients were evaluated for 48 weeks. RESULTS: Mean BCVA change at 48 weeks was + 0.2 and +15 letters with SF or RFPDT plus ranibizumab, respectively, compared with +16.8 letters with RM. At 48 weeks, mean central foveal thickness (CFT) decrease from baseline was 58 ± 15 μm, 91.4 ± 43.8 μm, and 85 ± 41.5 μm for the verteporfin SF, RF and RM groups, respectively. Macular sensitivity improvement was + 0.4 db, + 1.9 dB and + 2.7 dB for the verteporfin SF, RF and RM groups, respectively. CONCLUSIONS:Ranibizumab monotherapy or combined with RF-PDT improved BCVA and macular sensitivity in patients affected by mCNV, whereas CFT results were reduced. SF-PDT combination regimen mostly stabilized vision at 48 weeks. Among all groups, the RF-PDT seemed to reduce the number of ranibizumab retreatments.
Authors: Peter K Kaiser; David S Boyer; Alan F Cruess; Jason S Slakter; Stefan Pilz; Annemarie Weisberger Journal: Ophthalmology Date: 2012-03-22 Impact factor: 12.079
Authors: Davide Allegrini; Diego Vezzola; Alfredo Borgia; Raffaele Raimondi; Tania Sorrentino; Domenico Tripepi; Elisa Stradiotto; Marco Alì; Giovanni Montesano; Mario R Romano Journal: J Clin Med Date: 2022-08-26 Impact factor: 4.964